



High-level Gentamicin Resistance among Clinical Isolates of Enterococci in Iran: a Systematic Review and Meta-analysis

Milad Shahini Shams Abadi¹, Asieh Taji², Fatemeh Salehi³, Hossein Kazemian⁴, Hamid Heidari⁵

¹ Department of Microbiology and Immunology, Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran

² Department of Bacteriology and Virology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

³ Modeling in Health Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran

⁴ Department of Microbiology, Faculty of Medicine, Ilam University of Medical Sciences, Ilam, Iran

⁵ Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Corresponding author: Hamid Heidari, Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran; E-mail: heidarii.hamid@gmail.com; Tel.: +98-9386312941

Received: 22 Apr 2020 ♦ **Accepted:** 1 June 2020 ♦ **Published:** 28 Feb 2021

Citation: Abadi MSS, Taji A, Salehi F, Kazemian H, Heidari H. High-level gentamicin resistance among clinical isolates of enterococci in Iran: A systematic review and meta-analysis. *Folia Med (Plovdiv)* 2021;63(1):15-23. doi: 10.3897/folmed.63.e53506.

Abstract

Enterococci have been considered as one of the most common causes of nosocomial infections. The spread of antibiotic resistance has posed a serious challenge to treating the enterococcal infections. High-level aminoglycosides resistance leads to failure in the synergistic combination therapy.

This study aimed to estimate the prevalence of high-level gentamicin resistance (HLGR) among clinical isolates of enterococci in Iran.

Systematic literature search was conducted in the Web of Science, PubMed, Scopus and Google Scholar electronic databases from articles which were published from April 2000 to September 2018. Literature search yielded 918 studies. Eligible studies were selected according to the defined inclusion and exclusion criteria. Statistical heterogeneity was estimated by Q statistic and the I² index. The Begg's rank correlation test and Egger's weighted regression tests were used to evaluate possible publication bias.

Nineteen studies were included in this review. According to the meta-analysis results, the prevalence of HLGR among *Enterococcus* spp. was 49.4% (95% CI: 42.2%-56.6%). It was estimated 44.3% (95% CI: 38.1%-50.8%) and 66.3% (95% CI: 51.4%-78.6%) for *E. faecalis* and *E. faecium*, respectively.

Since notable rate of HLGR in enterococci was seen in this analysis, improving the implementation of all aspects of the infection control programmes is required. Accurate and regular monitoring of infection control procedures are necessary for reducing the dissemination of such infections.

Keywords

Enterococcus, Iran, high-level gentamicin resistance (HLGR), meta-analysis, systematic review

INTRODUCTION

Enterococci are common inhabitants of the human gastrointestinal tract and they are known to be potent pathogens responsible for several infections in humans.¹ Enterococci have been considered as one of the most common causes of nosocomial infections worldwide.² The spread of antibiotic resistance has posed a serious challenge to the treatment of the enterococcal infections.³ Simultaneous prescription of aminoglycosides and cell wall active agents (such as β -lactams or vancomycin) will be synergistically effective against severe infections.⁴ In 1979, high-level aminoglycosides resistance in enterococci was initially described in the US.⁵ High-level resistance (HLR) to the aminoglycosides leads to failure in the synergistic combination therapy.^{4,6} Moreover, horizontal HLR associated genes transfer is common between various strains and it can increase the risk of the development and dissemination of such resistance in enterococci.⁷

According to available data, the prevalence rates of high-level gentamicin resistance (HLGR) in enterococci have been reported from several parts of Iran.^{1,8-11} However, there is no comprehensive analysis regarding HLGR amongst *Enterococcus* isolates, obtained from several infections in the country. Therefore, the aim of the present study was to assess the prevalence of HLGR among clinical isolates of enterococci in Iran using a systematic review and meta-analysis conforms to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses.

MATERIALS AND METHODS

Search strategies

A systematic literature search was conducted in the Web of Science, PubMed, Scopus, and Google Scholar electronic databases from papers that were published from April 2000 to September 2018 following the PRISMA (the Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The following keywords, “*Enterococcus*” or “*E. faecalis*” or *E. faecium* and “high level aminoglycoside resistant” or “high level gentamicin resistant” or “HLGR” in combination with “Iran” were searched as scientific terms in the present survey. We also searched bibliographies of retrieved articles for additional references.

Eligibility criteria and study selection

Cross-sectional or cohort studies that reported the prevalence of HLGR in Iran were considered. To determine the articles which had inclusion criteria, the titles, abstracts and full texts were screened independently by two reviewers and any discrepancies were resolved by consensus. The articles published in English or Persian language which were indexed in PubMed or Scopus with the follo-

wing characteristics were included: standard used methods for HLGR detection in *Enterococcus* strains and reported data on number of HLGR among *Enterococcus* strains. According to the Clinical and Laboratory Standards Institute (CLSI) guidelines¹², standard methods for detecting HLGR among *Enterococcus* strains are broth dilution, agar dilution, and disk diffusion methods by high-content gentamicin (120 μ g). Additionally, research that has been conducted by non-Iranian authors on the Iranian population or samples were also assessed. Studies with nonstandard methods and without report of HLGR prevalence were excluded. We also excluded studies which their sample size was less than 10 isolates, nonhuman studies, review articles, meta-analyses or systematic reviews, congress abstracts and duplicate publication of the same studies.

Data extraction and definitions

Data collection was performed in parallel by two authors and discrepancies were resolved by a third author. Data collected included: first author's name, the study performing time, publication date, the study setting, sample size (number of *Enterococcus*, *E. faecalis* and *E. faecium* isolates) and prevalence of HLGR.

Statistical analysis

Analysis of data was performed by Comprehensive Meta-Analysis Software v. 2.2 (Bio stat Company). Meta-analysis was performed using random effects model to estimate pooled prevalence and corresponding 95% confidence interval (CI). Statistical heterogeneity between and within groups was estimated by the Q statistic and the I^2 index. The Begg's rank correlation test and Egger's weighted regression tests were used to evaluate possible publication bias ($p < 0.05$ was considered indicative of a statistically significant publication bias).

RESULTS

The literature search yielded 918 studies, 856 were excluded based on their index and review of title and abstract, leaving 62 articles for full text review. Of 62 reviewed studies, HLGR was not detected in 22 studies according to the standard methods, 12 studies did not report the prevalence of *Enterococcus* or *Enterococcus* spp., 4 studies had sample size less than 10 isolates, and the results of 5 studies were unclear. Eventually, 19 eligible studies were chosen for final analysis. There were no overlapping study populations in the final review. **Fig. 1** shows the study selection process and reasons for exclusion. None of the included studies received direct funding from pharmaceutical companies. The full results of included articles, the prevalence of *E. faecalis* and *E. faecium* and the frequency of HLGR amongst them are presented in **Table 1**.




Figure 1. Summary of the literature search and study selection. HLGR: high-level gentamicin resistance.

Nineteen studies investigated the frequency of HLGR among *Enterococcus* spp. The pooled prevalence for HLGR among *Enterococcus* isolates was 49.4% (95% CI: 42.2%-56.6%) ranging from 15% to 96% (Fig. 2). There was a significant heterogeneity among the 19 studies ($\chi^2=301.393$; $p<0.001$; $I^2=94\%$). Additionally, Begg's and Egger's tests were performed to quantitatively evaluate the publication biases. The results of Begg's test ($z=0.42$, $p=0.67$) and Egger's test ($t=0.54$, $p=0.6$) showed no evidence of publication bias.

According to the included publications, in 15 studies the frequency of HLGR in *E. faecalis* strains was investigated. The pooled prevalence of HLGR among *E. faecalis* isolates was 44.3% (95% CI: 38.1%-50.8%) ranging from 24% to 65% (Fig. 3). There was a significant heterogeneity among the 15 studies ($\chi^2=111.703$; $p<0.001$; $I^2=87.47\%$). There was no evidence of publication bias according to Begg's rank correlation analysis ($z=0.1$, $p=0.92$). Egger's regression analysis also confirmed there is no evidence of publication bias ($t=1.08$, $p=0.3$).

Table 1. Characteristics of studies included in the meta-analysis

Author	Study Details				Size (n)			HLGR		
	Publication year	Years of study	City or Region	Diagnostic method	Sample size	<i>E. faecalis</i>	<i>E. faecium</i>	Total	<i>E. faecalis</i>	<i>E. faecium</i>
Feizabadi et al. ¹³	2003	2000-2001	Tehran	Broth microdilution method	59	59	-	18	18	-
Feizabadi et al. ¹⁴	2004	2000-2002	Tehran	Macro-broth dilution method	182	182	-	76	76	-
Feizabadi et al. ¹⁵	2006	2002-2004	Tehran	Broth microdilution method	114	79	35	59	42	17
Saifi et al. ¹⁶	2008	2005-2006	Tehran	Broth microdilution method	638	496	142	295	158	137
Emaneini et al. ¹⁷	2008	UN	Tehran	Agar dilution method	326	210	116	171	106	65
Soltan Dallal et al. ¹⁸	2008	2005-2006	Tehran	DDM by high-content gentamicin (120 µg)	147	104	43	98	64	34
Feizabadi et al. ¹⁹	2008	2006-2007	Tehran	DDM by high-content gentamicin (120 µg)	102	102	-	66	66	-
Aligholi et al. ²⁰	2009	UN	Tehran	Broth microdilution method	495	320	157	233	134	93
Saifi et al. ²¹	2009	2005-2006	Tehran	Broth microdilution method	320	-	75	48	-	-
Jabalameili et al. ²²	2009	2002-2004	Tehran	Agar dilution method	413	277	123	215	-	-
Hasani et al. ²³	2012	2008-2010	Northwest Iran	Agar dilution method	220	152	68	136	79	54
Dadfarma et al. ⁸	2013	2009	Tehran	Broth microdilution method	142	90	47	62	38	21
Behnood et al. ¹⁰	2013	2009-2011	Northwest Iran	Agar dilution method	111	89	22	36	23	13
Emaneini et al. ²⁴	2016	2012	Tehran	DDM by high-content gentamicin (120 µg)	27	19	8	26	-	-
Khani et al. ²⁵	2016	2011-2012	Kermanshah	Broth microdilution method	138	63	33	123	-	-
Esmailzadeh et al. ²⁶	2016	2013-2014	Kashan	Broth microdilution method	180	108	72	43	26	17
Heidari et al. ¹	2016	2013-2014	Tehran	Broth microdilution method	57	46	2	31	30	1
Heidari et al. ⁹	2017	2015-2016	Shiraz	DDM by high-content gentamicin (120 µg)	51	51	-	27	27	-
Amini et al. ¹¹	2018	2016	Kermanshah	DDM by high-content gentamicin (120 µg)	108	94	14	46	33	13


DDM: disk diffusion method

We found 10 articles which investigated the frequency of HLGR in *E. faecium* isolates (one study was excluded because the sample size for *E. faecium* was less than ten). The pooled prevalence of HLGR in *E. faecium* isolates was 66.3% (95% CI: 51.4%-78.6%) ranging from 24% to 96% (Fig. 4). Based on Q statistic and the I² index, heterogeneity was significant ($\chi^2=100.387$; $p<0.001$; $I^2=91\%$). Also, the Begg's rank correlation analysis ($z=1.25$, $p=0.21$) and

Egger's regression analysis ($t=1.2$, $p=0.26$) confirmed no evidence of publication bias.


DISCUSSION

To the best of our knowledge, this study is the first systematic review regarding the prevalence of HLGR amongst




Meta Analysis

Figure 2. Forest plot of prevalence of HLGR among *Enterococcus* spp. in Iran.



Meta Analysis

Figure 3. Forest plot of prevalence of HLGR among *E. faecalis* isolates in Iran.



Meta Analysis

Figure 4. Forest plot of prevalence of HLGR among *E. faecium* isolates in Iran.

enterococci that caused several infections in Iran. According to the meta-analysis results, the pooled prevalence of high-level gentamicin resistant *Enterococcus* isolates was 49.4% (95% CI: 42.2%-56.6%). The prevalence of HLGR in *Enterococcus* in Iran is more than the one reported in a previous investigation in a neighbor country, Kuwait (14%).²⁷ However, high rates of HLGR in enterococcal bacteremia have been described in industrialized countries such as Korea (63%) and Spain (60.4%).^{28,29}

Our results indicated that the pooled prevalence of high-level gentamicin resistant *E. faecalis* isolates was 44.3% (95% CI: 38.1%-50.8%). More rates have been reported from Saudi Arabia (75.3%) and Taiwan (60%).^{30,31} The prevalence of HLGR in *E. faecalis* in Iran was more than that in other countries such as Japan (34.2%), Turkey (30%), Kuwait (14.7%), and USA (15%).^{27,32-34} Nevertheless, notable HLGR prevalence of bacteremia causative *E. faecalis* strains has been reported from Spain (62.9%), China (40.9%), Denmark (38.2%), New Zealand (38%), and Japan (32%).^{29,35-38}

Based on the meta-analysis results, the pooled prevalence of HLGR in *E. faecium* isolates was 66.3% (95% CI: 51.4%-78.6%) in Iran. It is more than the prevalence in two other Asian countries such as Kuwait (15.6%) and Japan (9.2%).^{27,32} Also, higher rates of HLGR in *E. faecium* (Up to 88%) has been described in Turkey.³³ However, high prevalence of high-level gentamicin resistant *E. faecium* isolated from blood stream was reported from developed countries such as Canada (71.6%), Denmark (64.4%), and Spain (53.8%).^{29,35,39} It was lower for China (43.2%), New Zealand (25%), and Japan (24%).³⁶⁻³⁸ The mentioned data, suggested that high-level gentamicin resistant strains pos-

sess significant ability to cause invasive infections such as blood stream infection.

Prevalence of resistant enterococcal strains amongst patients may be due to several factors; recently, various studies described the effects of diet on gut microbiota composition. Special diet such as fiber (as a non-digestible carbohydrate) consumption change *Enterococcus* species population in gastrointestinal tract.^{40,41} Also, drug-resistant *Enterococcus* isolates of animal origin can easily contaminate the food chain and infect humans and affect the intestinal colonization.^{42,43} Hospitalization of colonized patients by such strains may lead to dissemination of drug-resistant strains in hospital environment and among patients. Therefore, diverse ranges of high-level gentamicin resistant enterococci isolated from hospitalized patients in various countries may be related to their diverse dietary habits.

Enterococci are able to survive under environmental stresses such as dryness and selective antimicrobial pressure. Therefore, hospital setting has an important role in the spread of resistant strains among patients and high-quality disinfection and cleaning of all surfaces and medical equipment are necessary.⁴⁴⁻⁴⁶ Inadequate efficacy of utilized disinfectant due to reduced biocide sensitivity in enterococci may be one of the major issues in the infection control implementation in hospitals.

In addition, unfavourable condition may induce viable-but-nonculturable (VBNC) strains.⁴⁴ This phenomenon can lead to transmission of resistant strains among patients, despite the effective appearance of the infection control policies.

Emergence of drug-resistant bacteria has accelerated by overuse and misuse of antibiotics.^{47,48} Ineffective ami-

noglycosides prescription may contribute to selection of high-level gentamicin resistant strains. Colonization and dissemination of selected strains in hospital enhance the prevalence of HLGR among hospitalized patients.

HLGR in enterococci often occurs through acquisition of *aph(2'')-Ia-aac(6')-Ie* gene.⁷ This bifunctional gene is most commonly located on a transposon. Therefore, horizontal gene exchange and acquired HLR traits will occur quickly among colonized *Enterococcus* spp. Other HLGR encoding genes are most frequently in *E. faecium*.⁷ It can explain the greater prevalence of HLGR among *E. faecium* strains.

Considering the mentioned features of enterococci, it seems that the most effective strategy among the many possible strategies for reducing the transmission of healthcare-associated infections, is hand hygiene compliance amongst healthcare workers. As mentioned in a previous systematic review in Iran, training of healthcare workers seems to be necessary for prevention and control of nosocomial infections.⁴⁹

There are some limitations to the present review. First, only the published articles which were indexed in PubMed or Scopus were included in this meta-analysis. Secondly, few studies had been performed in different region of the country and most of the evaluated articles were related to Tehran (the capital of Iran).

CONCLUSIONS

The present systematic review indicates notable prevalence of high-level resistance to gentamicin amongst *Enterococcus* species in Iranian patients. According to the papers published from April 2000 to September 2018, diverse ranges were reported from Iran. This comprehensive analysis showed that, the prevalence of high-level gentamicin resistant *Enterococcus* spp. was 49.4%. Also, the prevalence of HLGR in *E. faecium* strains was greater than that in *E. faecalis*. Therefore, improving the implementation of all aspects of the infection control programs according to the international standards is necessary.

Conflict of Interest

All authors declare no conflicts of interest.

Funding

No funding.

REFERENCES

1. Heidari H, Emaneini M, Dabiri H, et al. Virulence factors, antimicrobial resistance pattern and molecular analysis of Enterococcal strains

isolated from burn patients. *Microb Pathog* 2016; 90:93–7.

2. Guzman Prieto AM, van Schaik W, Rogers MR, et al. Global emergence and dissemination of Enterococci as nosocomial pathogens: attack of the clones? *Front Microbiol* 2016; 7:788.
3. Miller WR, Munita JM, Arias CA. Mechanisms of antibiotic resistance in enterococci. *Expert Rev Anti Infect Ther* 2014; 12(10):1221–36.
4. Arias CA, Contreras GA, Murray BE. Management of multidrug-resistant enterococcal infections. *Clin Microbiol Infect* 2010; 16(6):555–62.
5. O'Driscoll T, Crank CW. Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management. *Infect Drug Resist* 2015; 8:217–30.
6. Chow JW. Aminoglycoside resistance in enterococci. *Clin Infect Dis* 2000; 31(2):586–9.
7. Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. *Virulence* 2012; 3(5):421–33.
8. Dadfarma N, Imani Fooladi AA, Oskoui M, et al. High level of gentamicin resistance (HLGR) among enterococcus strains isolated from clinical specimens. *J Infect Public Health* 2013; 6(3):202–8.
9. Heidari H, Hasanpour S, Ebrahim-Saraie HS, et al. High incidence of virulence factors among clinical *Enterococcus faecalis* isolates in Southwestern Iran. *Infect Chemother* 2017; 49(1):51–6.
10. Behnood A, Farajnia S, Moaddab SR, et al. Prevalence of *aac(6')-Ie-aph(2'')-Ia* resistance gene and its linkage to Tn5281 in *Enterococcus faecalis* and *Enterococcus faecium* isolates from Tabriz hospitals. *Iran J Microbiol* 2013; 5(3):203–8.
11. Amini FM, Krimpour HAP, Ghaderi MM, et al. Prevalence of aminoglycoside resistance genes in *Enterococcus* strains in Kermanshah, Iran. *Iran J Med Sci* 2018; 43(5):487–93.
12. Wayne P. Clinical and Laboratory Standard Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 27th informational supplement. 2017 M100-S126.
13. Feizabadi MM, Aliahmadi A, Mobasheri F, et al. Phenotypic characteristics and population genetics of *Enterococcus faecalis* cultured from patients in Tehran during 2000-2001. *Can J Microbiol* 2003; 49(10):645–9.
14. Feizabadi MM, Asadi S, Zohari M, et al. Genetic characterization of high-level gentamicin-resistant strains of *Enterococcus faecalis* in Iran. *Can J Microbiol* 2004; 50(10):869–72.
15. Feizabadi MM, Maleknejad P, Asgharzadeh A, et al. Prevalence of aminoglycoside-modifying enzymes genes among isolates of *Enterococcus faecalis* and *Enterococcus faecium* in Iran. *Microb Drug Resist* 2006; 12(4):265–8.
16. Saifi M, Pourshafie MR, Eshraghian MR, et al. Anti-microbial resistance of Enterococci isolated from urinary tract infections in Iran. *Iran Biomed J* 2008; 12(3):185–90.
17. Emaneini M, Aligholi M, Aminshahi M. Characterization of glycopeptides, aminoglycosides and macrolide resistance among *Enterococcus faecalis* and *Enterococcus faecium* isolates from hospitals in Tehran. *Pol J Microbiol* 2008; 57(2):173–8.
18. Soltan-Dallal M, Pourshafie MR, Eshraghian MR. High-level gentamicin-resistant enterococcal isolates from urinary tract infection in Iran. *Infect Dis Clin Pract* 2008; 16(1):41–5.
19. Feizabadi M, Sayady S, Asadi S. Transposon Tn5281 is the main distributor of the aminoglycoside modifying enzyme gene among isolates of *Enterococcus faecalis* in Tehran hospitals. *Can J Microbiol* 2008; 54:887–90.
20. Aligholi M, Jabalameli F, Shahsavan S, et al. Antibiotic susceptibility

- pattern of gram-positive Cocci cultured from patients in three university hospitals in Tehran, Iran during 2001-2005. *Acta Med Iran* 2009; 47(4):329–34.
21. Saifi M, Pourshafie MR, Dallal MM, et al. Clonal groups of high-level gentamicin-resistant *Enterococcus faecium* isolated from municipal wastewater and clinical samples in Tehran, Iran. *Lett Appl Microbiol* 2009; 49(2):160–5.
 22. Jabalameli F, Shahsavan S, Sedaghat H, et al. Evaluation of antimicrobial susceptibility patterns of *Enterococci* isolated from patients in Tehran University of Medical Sciences Teaching Hospitals. *Acta Med Iran* 2009; 47(4):325–8.
 23. Hasani A, Sharifi Y, Ghotaslou R, et al. Molecular screening of virulence genes in high-level gentamicin-resistant *Enterococcus faecalis* and *Enterococcus faecium* isolated from clinical specimens in Northwest Iran. *Indian J Med Microbiol* 2012; 30(2):175–81.
 24. Emaneini M, Khoramian B, Jabalameli F, et al. Prevalence of high-level gentamicin-resistant *Enterococcus faecalis* and *Enterococcus faecium* in an Iranian hospital. *J Prev Med Hyg* 2016; 57(4):E197–e200.
 25. Khani M, Fatollahzade M, Pajavand H, et al. Increasing prevalence of aminoglycoside-resistant *Enterococcus faecalis* isolates due to the *aac(6′)-aph(2′)* gene: a therapeutic problem in Kermanshah, Iran. *Jundishapur J Microbiol* 2016; 9(3):e28923.
 26. Esmailzadeh M, Moniri R, Gilasi HR, et al. Distribution of gentamicin resistant genes of nosocomial *enterococcus* spp from intensive care unit of Shahid Beheshti Hospital in Kashan, Iran. *J Pure Appl Microbiol* 2016; 10(3):1919–26.
 27. Udo EE, Al-Sweih N, Phillips OA, et al. Species prevalence and antibacterial resistance of *enterococci* isolated in Kuwait hospitals. *J Med Microbiol* 2003; 52(Pt 2):163–8.
 28. Jang HC, Lee S, Song KH, et al. Clinical features, risk factors and outcomes of bacteremia due to *enterococci* with high-level gentamicin resistance: comparison with bacteremia due to *enterococci* without high-level gentamicin resistance. *J Korean Med Sci* 2010; 25(1):3–8.
 29. Garcia-Vazquez E, Albendin H, Hernandez-Torres A, et al. [Study of a cohort of patients with *Enterococcus* spp. Bacteraemia. Risk factors associated to high-level resistance to aminoglycosides]. *Rev Esp Quimioter* 2013; 26(3):203–13 [Article in Spanish].
 30. El-Kersh TA, Marie MA, Al-Sheikh YA, et al. Prevalence and risk factors of early fecal carriage of *Enterococcus faecalis* and *Staphylococcus* spp and their antimicrobial resistant patterns among healthy neonates born in a hospital setting in central Saudi Arabia. *Saudi Med J* 2016; 37(3):280–7.
 31. McDonald LC, Lauderdale TL, Shiau YR, et al. The status of antimicrobial resistance in Taiwan among Gram-positive pathogens: the Taiwan Surveillance of Antimicrobial Resistance (TSAR) programme, 2000. *Int J Antimicrob Agents* 2004; 23(4):362–70.
 32. Osuka H, Nakajima J, Oishi T, et al. High-level aminoglycoside resistance in *Enterococcus faecalis* and *Enterococcus faecium* causing invasive infection: Twelve-year surveillance in the Minami Ibaraki Area. *J Infect Chemother* 2016; 22(1):61–3.
 33. Erdem H, Oncul O. A review of the current place of glycopeptides in Turkish medical practice. *Curr Ther Res Clin Exp* 2007; 68(1):49–66.
 34. Chowdhury SA, Nallapareddy SR, Arias CA, et al. The majority of a collection of U.S. endocarditis *Enterococcus faecalis* isolates obtained from 1974 to 2004 lack capsular genes and belong to diverse, non-hospital-associated lineages. *J Clin Microbiol* 2014; 52(2):549–56.
 35. Pinholt M, Ostergaard C, Arpi M, et al. Incidence, clinical characteristics and 30-day mortality of enterococcal bacteraemia in Denmark 2006-2009: a population-based cohort study. *Clin Microbiol Infect* 2014; 20(2):145–51.
 36. Wang X, Zhao C, Li H, et al. [Microbiological profiles of pathogens causing nosocomial bacteremia in 2011, 2013 and 2016]. *Sheng Wu Gong Cheng Xue Bao* 2018; 34(8):1205–17 [Article in Chinese].
 37. Araoka H, Kimura M, Yoneyama A. A surveillance of high-level gentamicin-resistant enterococcal bacteremia. *J Infect Chemother* 2011; 17(3):433–4.
 38. McBride SJ, Upton A, Roberts SA. Clinical characteristics and outcomes of patients with vancomycin-susceptible *Enterococcus faecalis* and *Enterococcus faecium* bacteraemia - a five-year retrospective review. *Eur J Clin Microbiol Infect Dis* 2010; 29(1):107–14.
 39. McCracken M, Wong A, Mitchell R, et al. Molecular epidemiology of vancomycin-resistant enterococcal bacteraemia: results from the Canadian Nosocomial Infection Surveillance Program, 1999-2009. *J Antimicrob Chemother* 2013; 68(7):1505–9.
 40. Tomova A, Bukovsky I, Rembert E, et al. The effects of vegetarian and vegan diets on gut microbiota. *Front Nutr* 2019; 6:47.
 41. Rinninella E, Cintoni M, Raoul P, et al. Food components and dietary habits: keys for a healthy gut microbiota composition. *Nutrients* 2019; 11(10):2393.
 42. Torres C, Alonso CA, Ruiz-Ripa L, et al. Antimicrobial resistance in *Enterococcus* spp. of animal origin. *Microbiol Spectrum* 2018;6(4):ARBA-0032-2018. doi:10.1128/microbiolspec.ARBA-0032-2018
 43. Manson AL, Van Tyne D, Straub TJ, et al. Chicken meat-associated *Enterococci*: influence of agricultural antibiotic use and connection to the clinic. *Appl Environ Microbiol* 2019;85(22).
 44. Byapanahalli MN, Nevers MB, Korajkic A, et al. *Enterococci* in the environment. *Microbiol Mol Biol Rev* 2012; 76(4):685–706.
 45. Agudelo Higuera NI, Huycke MM. Enterococcal disease, epidemiology, and implications for treatment. In: Gilmore MS, Clewell DB, Ike Y, Shankar N, editors. *Enterococci: From Commensals to Leading Causes of Drug Resistant Infection*. Boston: Massachusetts Eye and Ear Infirmary; 2014.
 46. Mehta Y, Gupta A, Todi S, et al. Guidelines for prevention of hospital acquired infections. *Indian J Crit Care Med* 2014; 18(3):149–63.
 47. Alp E, Damani N. Healthcare-associated infections in intensive care units: epidemiology and infection control in low-to-middle income countries. *J Infect Dev Ctries* 2015; 9(10):1040–45.
 48. Llor C, Bjerrum L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther Adv Drug Saf* 2014; 5(6):229–41.
 49. Emaneini M, Beigverdi R, van Leeuwen WB, et al. Prevalence of methicillin-resistant *Staphylococcus aureus* isolated from burn patients in Iran: A systematic review and meta-analysis. *J Glob Antimicrob Resist* 2018; 12:202–6.

Устойчивость к гентамицину высокого уровня среди клинических изолятов энтерококков в Иране: систематический обзор и метаанализ

Милад Шахини Шамс Абади¹, Асиех Таджи², Фатемех Салехи³, Хосеин Каземиан⁴, Хамид Хеидари⁵

¹ Кафедра микробиологии и иммунологии, Центр клеточных и молекулярных исследований, Институт фундаментальных медицинских наук, Университет медицинских наук Шахрекорд, Шахрекорд, Иран.

² Кафедра бактериологии и вирусологии, Медицинский факультет, Ширазский университет медицинских наук, Шираз, Иран

³ Исследовательский центр медицинского моделирования, Университет медицинских наук Шахрекорд, Шахрекорд, Иран.

⁴ Кафедра микробиологии, Медицинский факультет, Иламский университет медицинских наук, Илам, Иран

⁵ Кафедра микробиологии, Медицинский факультет, Университет медицинских наук, Шахида Садуги, Йезд, Иран

Адрес для корреспонденции: Хамид Хеидари, Кафедра микробиологии, Медицинский факультет, Университет медицинских наук Шахида Садуги, Йезд, Иран; E-mail: heidarii.hamid@gmail.com; Tel.: +98-9386312941

Дата получение: 22 апреля 2020 ♦ **Дата приемки:** 1 июня 2020 ♦ **Дата публикации:** 28 февраля 2021

Образец цитирования: Abadi MSS, Taji A, Salehi F, Kazemian H, Heidari H. High-level gentamicin resistance among clinical isolates of enterococci in Iran: A systematic review and meta-analysis. *Folia Med (Plovdiv)* 2021;63(1):15-23. doi: 10.3897/folmed.63.e53506.

Резюме

Enterococci считаются одной из наиболее частых причин внутрибольничных инфекций. Высокая устойчивость к аминогликозидам приводит к недостаточности синергетической комбинированной терапии.

Целью этого исследования было оценить частоту высокой устойчивости к гентамицину (HLGR) среди клинических изолятов энтерококков в Иране.

Был проведен систематический обзор литературы в электронных базах данных Web of Science, PubMed, Scopus и Google Scholar на предмет поиска статей, опубликованных с апреля 2000 г. по сентябрь 2018 г. Поиск в доступной литературе выявил 918 исследований. Подходящие исследования были отобраны в соответствии с заранее определенными критериями включения и исключения. Статистическая неоднородность измерялась Q-статистикой и индексом I². Для оценки возможной субъективности публикаций использовались тест ранговой корреляции Бегга и регрессионный тест Эгера.

В этот обзор было включено девятнадцать исследований. По результатам метаанализа частота HLGR к *Enterococcus* spp. составила 49.4% (95% CI: 42.2% -56.6%). Результаты показали 44.3% (95% CI: 38.1% -50.8%) и 66.3% (95% CI: 51.4% -78.6%) для *E. faecalis* и *E. faecium*, соответственно.

Поскольку в ходе этого анализа была обнаружена высокая частота HLGR в отношении enterococci, мы пришли к выводу, что необходимо улучшить все аспекты процедур инфекционного контроля, чтобы уменьшить распространение таких инфекций.

Ключевые слова

Enterococcus, Иран, высокая устойчивость к гентамицину (HLGR), метаанализ, систематический обзор